In the premarket trading session, at last check AGE stock surged by 7.2% to $1.34. AGE stock closed previous session at $1.25 losing -3.85%. The AGE stock volume traded 80189.0 shares. In the past year up-to-date AGE stock had jumped by 64.47% while in the past week the shares shed -6.02%
What is the business update on the AGE stock?
On 1st April 2021, the AgeX Therapeutics Inc. announced the business update and release of financial results of the fourth quarter 2020.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
The company had recently entered into a supported sponsored collaboration with The Ohio State Universit. This coordination is focused on the utilization of AgeX-BAT1 in mice. This candidate is based on AgeX’s brown adipocyte tissue (BAT) cell treatment. The purpose of it is to decide if transplantation of AgeX-BAT1 cells may improve cardiovascular capacity, diet-incited obesity and metabolic wellbeing including glucose digestion.
AgeX has also partnered with a biopharmaceutical organization creating embryonic stem cell (ESC) derived mesenchymal stem cells (MSCs) known as ImStem Biotechnology Inc. The collaboration was based on non-exclusive sublicense that will contain royalties for the utilization of AgeX’s clinical-grade ESC line ESI-053 to determine ImStem’s investigational MSC item candidate IMS001 for improvement in COVID-19 as well as acute respiratory distress disorder (ARDS) from different causes. ImStem’s MSC item up-and-comer IMS001 is based on AgeX’s stem cell line ESI-053. In March 2020, IMS001 acquired FDA IND approval to start a human research in different sclerosis.
AgeX reported on March 12, 2021 the online distribution of research paper identifying with regeneration, maturing, and cancer in bioRxiv. The paper presents interesting information identifying with mechanisms that cells may use during the recovery period. The paper uncovers changes in specific qualities that may keep recovery from happening in aged people. It additionally gives proof that the group of qualities might be engaged with a wide exhibit of human tumors.
The company provides financial updates on AGE stock
The fourth quarter and full year result for the year 2020 has overall positively improved as compared to the year 2019. When we look at the highlights posted by the company we see that the company for the fourth quarter of 2020 reported Total Revenues of $0.5 million. While for the year ended December 31, 2020 the total revenues were $1.9 million, compared to $1.7 million in the same period in 2019. The company increased the Operating expenses by $2 million to $12.4 million in full year 2020 as compared to 2019. The net loss attributable for AGE stock equals $0.29 per share in 2020 compared to $0.33 per share for the period 2019.
About AgeX Therapeutics, Inc.
AgeX Therapeutics, Inc.,is a biotechnology company that specifically centers around the design, developmentand commercialization of novel therapeutics. These novel treatments areprimarily for human aging and degenerative illnesses. The organization was established in 2017 and is situated in Alameda,California.The company has its operations deployed in the market of United States. The organization’s lead cell-based helpful candidate being developed consists of AGEX-BAT1, a cell treatment product for the treatment of different age-related metabolic issues, for example, Type II adult on-set diabetes.AgeX Therapeutics, Inc. has a research coordinated effort with the University of California, Irvine on neural foundational cell research program for Huntington’s sickness and other neurological disorders; and Sernova Corp.
The company also provides AGEX-VASC1, a cell-based treatment to reestablish vascular aid in ageing ischemic tissues, like the ischemic heart. Its lead drug-based investigative candidate is AGEX-iTR1547, for restoration of regenerative potential in a range of aged tissues affected by degenerative infections. Furthermore, the organization markets human embryonic stem cells; and GeneCards Database Suite, including genomic analysis calculations and analysis instruments for use by specialists at drug and biotechnology organizations, and different establishments.
